AG-024322 - CAS 837364-57-5
Catalog number: 837364-57-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C23H20F2N6
Molecular Weight:
418.452
COA:
Inquire
Description:
AG-24322 is a second generation CDK inhibitor. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models.
Purity:
0.98
Appearance:
white solid powder
Synonyms:
AG-24322.
MSDS:
Inquire
InChIKey:
RBOKLZGCVRXGEP-XTQSDGFTSA-N
InChI:
InChI=1S/C23H20F2N6/c1-3-26-9-14-10-27-11-17(12(14)2)13-4-5-19-16(6-13)21(31-30-19)23-28-20-8-15(24)7-18(25)22(20)29-23/h4-8,10-11,26,30-31H,3,9H2,1-2H3/b23-21+
Canonical SMILES:
CCNCC1=C(C(=CN=C1)C2=CC3=C(C=C2)NNC3=C4N=C5C=C(C=C(C5=N4)F)F)C
Current Developer:
Pfizer
1.Application of electroretinography (ERG) in early drug development for assessing retinal toxicity in rats.
Huang W1, Collette W 3rd2, Twamley M2, Aguirre SA2, Sacaan A2. Toxicol Appl Pharmacol. 2015 Dec 15;289(3):525-33. doi: 10.1016/j.taap.2015.10.008. Epub 2015 Oct 19.
Retinal ocular toxicity is among the leading causes of drug development attrition in the pharmaceutical industry. Electroretinography (ERG) is a non-invasive functional assay used to assess neuro-retinal physiological integrity by measuring the electrical responses. To directly assess the utility of ERG, a series of studies was conducted following intravitreal and/or iv administration of pan-cyclin-dependent kinase inhibitors: AG-012,986 and AG-024,322 in rats. Both compounds have previously shown to induce retinal toxicity. Retinal injury was evaluated by ERG, histopathology and TUNEL staining. Intravitreal injection of AG-012,986 at ≥ 10 μg/eye resulted in decreases (60%) in ERG b-wave and microscopic changes of mild to moderate retinal degeneration, and at 30 μg/eye led to additional ophthalmic findings. Intravenous administration of AG-012,986 daily at ≥ 5 mg/kg resulted in dose-related decreases (25 to 40%) in b-wave and sporadic to intense positive TUNEL staining.
2.Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Johnson N1, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Nat Med. 2011 Jun 26;17(7):875-82. doi: 10.1038/nm.2377.
Cells that are deficient in homologous recombination, such as those that lack functional breast cancer-associated 1 (BRCA1) or BRCA2, are hypersensitive to inhibition of poly(ADP-ribose) polymerase (PARP). However, BRCA-deficient tumors represent only a small fraction of adult cancers, which might restrict the therapeutic utility of PARP inhibitor monotherapy. Cyclin-dependent kinase 1 (Cdk1) phosphorylates BRCA1, and this is essential for efficient formation of BRCA1 foci. Here we show that depletion or inhibition of Cdk1 compromises the ability of cells to repair DNA by homologous recombination. Combined inhibition of Cdk1 and PARP in BRCA-wild-type cancer cells resulted in reduced colony formation, delayed growth of human tumor xenografts and tumor regression with prolonged survival in a mouse model of lung adenocarcinoma. Inhibition of Cdk1 did not sensitize nontransformed cells or tissues to inhibition of PARP. Because reduced Cdk1 activity impaired BRCA1 function and consequently, repair by homologous recombination, inhibition of Cdk1 represents a plausible strategy for expanding the utility of PARP inhibitors to BRCA-proficient cancers.
3.Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion.
Brown AP1, Courtney CL, Criswell KA, Holliman CL, Evering W, Jessen BA. Cancer Chemother Pharmacol. 2008 Nov;62(6):1091-101. doi: 10.1007/s00280-008-0771-1. Epub 2008 May 29.
PURPOSE: Cyclin-dependent kinases (CDKs) play a significant role in the control of cell-cycle progression and exhibit aberrant regulation in various neoplastic diseases. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models. This study evaluated the toxicity of AG-024322 when given by intravenous (IV) infusion to cynomolgus monkeys, including reversibility of effects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 1194044-20-6 LY2811376

LY2811376
(CAS: 1194044-20-6)

LY2811376, under the IUPAC name (4S)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine, is the first orally available non-peptidi...

SB-408124 (Hydrochloride)
(CAS: 1431697-90-3)

SB-408124 (Hydrochloride) is the hydrochloride salt form of SB-408124. SB-408124 is a selective antagonist of OX1 (for human OX1 Kb= 21.7nM; for human OX2 Kb=14...

CAS 1164153-22-3 SR 3576

SR 3576
(CAS: 1164153-22-3)

SR 3576 is a potent and selective JNK3 inhibitor (IC50 = 7 nM) with > 2800-fold selectivity over p38.

CAS 189353-32-0 Fadolmidine HCl

Fadolmidine HCl
(CAS: 189353-32-0)

Fadolmidine Hydrochloride, is a novel α2-adrenoceptor (α2-AR) agonist, having antinociception properties. It can be used for the control of inflammatory, postop...

C14TKL-1

C14TKL-1 is an endogenous human tachykinin-like peptide and a potent NK1 receptor agonist (EC50 = 1 nM).

CAS 1126084-37-4 ASP-9521

ASP-9521
(CAS: 1126084-37-4)

ASP9521 is a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ASP9521 has demonstrated anti-tumour ...

CAS 1137264-00-6 cis-Ned 19

cis-Ned 19
(CAS: 1137264-00-6)

cis-Ned 19 is a irreversible nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist, which inhibits Ca2+ release (IC50 = 800 nM) and [32P]NAADP bindin...

CAS 1028141-88-9 RuBi-GABA

RuBi-GABA
(CAS: 1028141-88-9)

RuBi-GABA, a ruthenium-bipyridine-triphenylphosphine caged GABA, is a photolabile protecting group used for highly efficient visible light GABA uncaging.

Chemical Structure

CAS 837364-57-5 AG-024322

Quick Inquiry

Verification code

Featured Items